• Featured Product
  • KD/KO Validated

CoraLite® Plus 488-conjugated Alpha Galactosidase A Monoclonal antibody

Alpha Galactosidase A Monoclonal Antibody for IF/ICC
Cat No. CL488-66121

Host / Isotype

Mouse / IgG2a

Reactivity

human

Applications

IF/ICC

Alpha D galactosidase A, Alpha galactosidase A, GALA, galactosidase, alpha, GLA, Melibiase

Formulation:  PBS and Azide
PBS and Azide
Conjugate:  CoraLite® Plus 488
Size/Concentration: 

-/ -

Freight/Packing: -

Quantity

Please visit your regions distributor:


Tested Applications

Positive IF/ICC detected inHepG2 cells

Recommended dilution

ApplicationDilution
Immunofluorescence (IF)/ICCIF/ICC : 1:50-1:500
It is recommended that this reagent should be titrated in each testing system to obtain optimal results.
Sample-dependent, Check data in validation data gallery.

Product Information

CL488-66121 targets Alpha Galactosidase A in IF/ICC applications and shows reactivity with human samples.

Tested Reactivity human
Host / Isotype Mouse / IgG2a
Class Monoclonal
Type Antibody
Immunogen Alpha Galactosidase A fusion protein Ag7505 Predict reactive species
Full Name galactosidase, alpha
Calculated Molecular Weight 49 kDa
Observed Molecular Weight 49 kDa
GenBank Accession NumberBC002689
Gene Symbol GLA
Gene ID (NCBI) 2717
RRIDAB_2883263
Conjugate CoraLite® Plus 488 Fluorescent Dye
Excitation/Emission Maxima Wavelengths493 nm / 522 nm
Form Liquid
Purification MethodProtein A purification
UNIPROT IDP06280
Storage Buffer PBS with 50% Glycerol, 0.05% Proclin300, 0.5% BSA, pH 7.3.
Storage ConditionsStore at -20°C. Avoid exposure to light. Stable for one year after shipment. Aliquoting is unnecessary for -20oC storage.

Background Information

GLA, also named as Melibiase and Alpha-galactosidase A, belongs to the glycosyl hydrolase 27 family. It hydrolyzes terminal, non-reducing alpha-D-galactose residues in alpha-D-galactosides, including galactose oligosaccharides, galactomannans and galactolipids. Fabry disease is an X-linked lysosomal storage disorder resulting from the deficient activity of GLA. Enzyme replacement therapy (ERT) with GLA is currently the most effective therapeutic strategy for patients with Fabry disease, a lysosomal storage disease.

Protocols

Product Specific Protocols
IF protocol for CL Plus 488 Alpha Galactosidase A antibody CL488-66121Download protocol
Standard Protocols
Click here to view our Standard Protocols
Loading...